RVSV-EBOV regulatory update

FDA granted breakthrough therapy designation and EMA granted PRIority MEdicines (PRIME) status to V920 to prevent Ebola virus infection. In 2014, NewLink’s BioProtection Systems subsidiary granted Mer...